$TOVX

Theriva Biologics (NYSE American: TOVX) reported Q2 2026 results and said first patients were dosed in the VIRAGE2 Phase 2a trial testing more frequent VCN-01 dosing in metastatic PDAC. The company reported $11.3M cash as of June 30, 2026. General and admin expenses fell to $2.0M and R&D to $1.3M.

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr

Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2020 Stock Incentive Plan On August 3, 2026, Theriva Biologics, Inc. (the “Company”) held its 2026 Annual Mee

Theriva Biologics (TOVX) said Spain’s AEMPS authorized its VIRAGE2 Phase 2a trial to test more frequent dosing of VCN-01 with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The trial aims to assess tolerability and whether repeated dosing affects VCN-01 levels, building on VIRAGE results.

Theriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.

Theriva Biologics is holding a special stockholder meeting on June 5, 2026, to approve the issuance of up to 16,184,560 shares of common stock upon the exercise of previously issued warrants at $0.54 per share. This approval could generate approximately $8.7 million in gross proceeds for the company, though it would dilute existing shareholders. Shareholders will also vote on adjourning the meeting if more votes are needed for the warrant exercise proposal.

Maxim Group has upgraded Theriva Biologics (NYSE:TBIO) from a Hold rating to a Buy rating. The firm also set a new price target of $9.00 for the company's stock. This upgrade suggests a positive outlook on Theriva Biologics' future performance.

This article provides a technical analysis and stock price forecast for Theriva Biologics Inc (TOVX) as of March 31, 2026. It indicates a neutral overall technical sentiment based on a combination of moving averages and oscillators. Key metrics such as RSI, MACD, support, resistance levels, and various moving averages are detailed, offering insights into the stock's current trading position and potential future movements.

Theriva Biologics Inc. stock surged 25.4% in premarket trading after the European Medicines Agency (EMA) provided positive scientific advice on the company's proposed Phase 3 clinical trial design for VCN-01 in pancreatic cancer treatment. The EMA agreed with key elements of the trial design, including sample size and a "macrocycle" dosing regimen allowing for multiple doses of VCN-01. Theriva plans to engage with the FDA in early 2026 to finalize the protocol for the multinational Phase 3 trial and is also seeking advice for a potential Phase 2/3 trial for VCN-01 in retinoblastoma.